BioInvent International AB (BOVNF)
4.70
0.00 (0.00%)
USD |
OTCM |
Jun 17, 16:00
BioInvent International Revenue (Quarterly): 0.5729M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.5729M |
| December 31, 2023 | 1.443M |
| September 30, 2023 | 2.484M |
| June 30, 2023 | 1.246M |
| March 31, 2023 | 1.559M |
| December 31, 2022 | 1.932M |
| September 30, 2022 | 1.709M |
| June 30, 2022 | 27.69M |
| March 31, 2022 | 1.788M |
| December 31, 2021 | 0.5551M |
| September 30, 2021 | 0.3465M |
| June 30, 2021 | 0.6291M |
| March 31, 2021 | 0.7405M |
| December 31, 2020 | 11.48M |
| September 30, 2020 | 1.838M |
| June 30, 2020 | 1.619M |
| March 31, 2020 | 1.738M |
| December 31, 2019 | 2.644M |
| September 30, 2019 | 1.884M |
| June 30, 2019 | 3.483M |
| March 31, 2019 | 1.899M |
| December 31, 2018 | 1.147M |
| September 30, 2018 | 0.7878M |
| June 30, 2018 | 1.131M |
| March 31, 2018 | 1.398M |
| Date | Value |
|---|---|
| December 31, 2017 | 1.627M |
| September 30, 2017 | 0.8787M |
| June 30, 2017 | 1.291M |
| March 31, 2017 | 1.454M |
| December 31, 2016 | 3.406M |
| September 30, 2016 | 0.0953M |
| June 30, 2016 | 1.255M |
| March 31, 2016 | 3.478M |
| December 31, 2015 | 1.174M |
| September 30, 2015 | 0.1965M |
| June 30, 2015 | 0.4344M |
| March 31, 2015 | 0.074M |
| December 31, 2014 | 0.225M |
| September 30, 2014 | 1.592M |
| June 30, 2014 | 4.918M |
| March 31, 2014 | 0.2731M |
| December 31, 2013 | 7.678M |
| September 30, 2013 | 1.195M |
| June 30, 2013 | 1.873M |
| March 31, 2013 | 1.809M |
| December 31, 2012 | 1.399M |
| September 30, 2012 | 1.911M |
| June 30, 2012 | 0.9005M |
| March 31, 2012 | 2.150M |
| December 31, 2011 | 0.2723M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.3465M
Minimum
Sep 2021
27.69M
Maximum
Jun 2022
3.369M
Average
1.724M
Median
Revenue (Quarterly) Benchmarks
| Abliva AB | -- |
| Karolinska Development AB | 0.0454M |
| Calliditas Therapeutics AB | 28.49M |
| Oncopeptides AB | 0.26M |
| Olink Holding AB | 28.75M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -7.515M |
| Total Expenses (Quarterly) | 9.223M |
| EPS Diluted (Quarterly) | -0.1138 |
| Enterprise Value | 209.39M |
| Profit Margin (Quarterly) | -1.31K% |
| Earnings Yield | -10.22% |
| Normalized Earnings Yield | -11.01 |